Suggested remit: To appraise the clinical and cost effectiveness of pegcetacoplan within its marketing authorisation for treating adults with geographic atrophy.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information Scoping commencing
Process STA Standard
ID number 4041

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter


Companies sponsors Apellis (pegcetacoplan)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Macular Society
Professional groups Royal College of Ophthalmologists
  Royal College of Physicians
Associated public health groups None
Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups None


Key events during the development of the guidance:

Date Update
03 April 2024 Following a regulatory update from the company, the timelines for this appraisal are to be confirmed.
16 August 2023 Invitation to participate
19 July 2023 Stakeholder workshop
26 May 2023 - 26 June 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4041
26 May 2023 In progress

For further information on our processes and methods, please see our CHTE processes and methods manual